PH12020551418A1 - Methods of use and pharmaceutical compositions of a selective syk inhibitor - Google Patents

Methods of use and pharmaceutical compositions of a selective syk inhibitor

Info

Publication number
PH12020551418A1
PH12020551418A1 PH12020551418A PH12020551418A PH12020551418A1 PH 12020551418 A1 PH12020551418 A1 PH 12020551418A1 PH 12020551418 A PH12020551418 A PH 12020551418A PH 12020551418 A PH12020551418 A PH 12020551418A PH 12020551418 A1 PH12020551418 A1 PH 12020551418A1
Authority
PH
Philippines
Prior art keywords
methods
pharmaceutical compositions
syk inhibitor
selective
selective syk
Prior art date
Application number
PH12020551418A
Other languages
English (en)
Inventor
Anjali Pandey
Matthew Chapin
Harold Patterson
Yung Yueh Hsu
Mark Abelson
Original Assignee
Portola Pharm Inc
Ora Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc, Ora Inc filed Critical Portola Pharm Inc
Publication of PH12020551418A1 publication Critical patent/PH12020551418A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12020551418A 2018-03-09 2020-09-09 Methods of use and pharmaceutical compositions of a selective syk inhibitor PH12020551418A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641094P 2018-03-09 2018-03-09
US201862663999P 2018-04-27 2018-04-27
PCT/US2019/021402 WO2019173744A1 (en) 2018-03-09 2019-03-08 Methods of use and pharmaceutical compositions of a selective syk inhibitor

Publications (1)

Publication Number Publication Date
PH12020551418A1 true PH12020551418A1 (en) 2021-09-01

Family

ID=65818744

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551418A PH12020551418A1 (en) 2018-03-09 2020-09-09 Methods of use and pharmaceutical compositions of a selective syk inhibitor

Country Status (15)

Country Link
US (1) US20210052582A1 (https=)
EP (1) EP3761986A1 (https=)
JP (1) JP7417531B2 (https=)
KR (1) KR20210018193A (https=)
CN (2) CN112243375A (https=)
AU (1) AU2019230220B2 (https=)
BR (1) BR112020018377A2 (https=)
CA (1) CA3093371A1 (https=)
IL (1) IL277093A (https=)
MX (1) MX2020009396A (https=)
PH (1) PH12020551418A1 (https=)
SG (1) SG11202008765UA (https=)
TW (1) TWI805705B (https=)
WO (1) WO2019173744A1 (https=)
ZA (1) ZA202005459B (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
KR101454674B1 (ko) 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
MX2010011463A (es) * 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
SG2014015085A (en) * 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
KR20140103168A (ko) * 2011-12-16 2014-08-25 알러간, 인코포레이티드 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
EP2897950A1 (en) * 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors

Also Published As

Publication number Publication date
SG11202008765UA (en) 2020-10-29
US20210052582A1 (en) 2021-02-25
TWI805705B (zh) 2023-06-21
AU2019230220A1 (en) 2020-10-08
KR20210018193A (ko) 2021-02-17
MX2020009396A (es) 2021-01-15
IL277093A (en) 2020-10-29
BR112020018377A2 (pt) 2021-03-09
AU2019230220B2 (en) 2025-01-30
CN119235862A (zh) 2025-01-03
JP2021517139A (ja) 2021-07-15
CA3093371A1 (en) 2019-09-12
EP3761986A1 (en) 2021-01-13
JP7417531B2 (ja) 2024-01-18
WO2019173744A1 (en) 2019-09-12
CN112243375A (zh) 2021-01-19
ZA202005459B (en) 2023-02-22
TW202002980A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
SA522433000B1 (ar) مركبات فلورو ألكيل-أوكساديازول واستخداماتها
EA202191177A1 (ru) 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP3693369A3 (en) Bromodomain inhibitors
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
AU2017261303A1 (en) Ophthalmic compositions
ZA202212095B (en) Il4i1 inhibitors and methods of use
MY203280A (en) Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
MX2021007247A (es) Derivados de rapamicina.
MX2021002042A (es) Inhibidores de arginasa y sus metodos de uso.
MX2019004375A (es) Inhibidores de bromodominios.
EA202092579A1 (ru) Оксозамещенное соединение
MX2023001721A (es) Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer.
AU2019296118A8 (en) Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same
EP4257189A3 (en) Pharmaceutical combination comprising a biguanid and an acetylcholinesterase inhibitor for use in age-related and/or degenerative diseases
PH12020551418A1 (en) Methods of use and pharmaceutical compositions of a selective syk inhibitor